SAGE Therapeutics, Inc.

As of February 24, 2022, SAGE Therapeutics, Inc. is considered risky and overvalued due to poor financial metrics, including a price-to-book ratio of 1.05, a negative return on equity of -81.01%, and underperformance compared to its peer Ironwood Pharmaceuticals and the S&P 500.

As of February 24, 2022, SAGE Therapeutics, Inc. is considered overvalued and risky due to negative financial metrics, including a non-applicable P/E ratio, an EV to EBITDA ratio of -0.02, and a significant decline in long-term returns, despite a strong year-to-date performance.

As of June 17, 2025, the technical trend is bullish with strong daily moving averages and a bullish weekly MACD, though caution is advised due to mixed signals from the monthly indicators.

SAGE Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $14 million and a net loss of $62 million. It has a market cap of $571.13 million and key metrics indicating it is currently unprofitable.

As of Jun 18, SAGE Therapeutics, Inc. has a market capitalization of 571.13 million and reported net sales of 47.40 million with a net profit of -354.39 million over the latest four quarters. Shareholder's funds are 465.09 million, and total assets amount to 547.22 million.